# **Testicular Cancer: Peer-Reviewed Analysis**

This document has undergone peer review by an independent group of scientific experts in the field.

# **Testicular Cancer**

Ted Schettler, MD, MPH Science Director, Science and Environmental Health Network

## February 2003

Testicular cancer is the most common cancer in young men (ages 15-45). In the testes, cancer of the germ cells (immature sperm) is by far the most frequent, though cancer of the testosterone-producing Leydig cells can also occur. Fortunately, treatment for testicular cancer has markedly improved over the past several decades, and the disease is frequently curable with combinations of surgery, chemotherapy, and radiation. As a result, mortality from testicular cancer has declined, but the incidence of new cases has steadily increased in many countries since the 1940's.

# Epidemiology

In the United States, the incidence of testicular cancer dramatically increased by nearly 300% between the late 1930s and late 1970s. Over the past 25 years, incidence has continued to increase at about 2.2% annually for white men, while remaining nearly constant for black men.<sup>1 2</sup> The rate of increase has been even sharper in some countries, including the United Kingdom and Denmark, where testicular cancer incidence is the highest in the world.<sup>3</sup>

Low and relatively constant incidence rates of testicular cancer are seen not only in black men in the United States but also in Africans, Asians, and, South Americans. Rates among Japanese and Chinese migrants to the US, however, are higher than among those living in Asia, suggesting that environmental as well as genetically-determined ethnic factors are involved in the origins of this cancer.<sup>4</sup>

#### **Causes of Testicular Cancer**

The cause(s) of testicular cancer are not well understood, but the age distribution of the disease, twin studies, studies of the uterine environment during fetal development, laboratory animal studies, and identification of risk factors provide important clues.

#### **Genetic Inheritance**

The familial relative risk of testicular cancer is higher than in many cancers. Brothers of men with testicular cancer have an approximately 8 fold increased risk of developing the disease.<sup>5</sup> Two studies conclude that 25-33% of testicular cancer cases result from genetic predisposition.<sup>6 7</sup> However, these studies must be interpreted with caution because shared environmental factors as well as genetic inheritance may influence the outcome of studies of cancer incidence in families.

#### **Environmental Factors**

The fetal and childhood environment is a particularly important determinant of testicular cancer risk. Fetal environmental factors include maternal hormone levels and chemicals that cross the placenta, directly exposing the fetus during critical periods of development. An analysis of a large Swedish database of cancer in families concludes that childhood and non-shared environmental factors together account for about 75% of testicular cancer cases.<sup>8</sup>

It is important to consider the well-documented increased rate of testicular cancer in the context of other apparent changes in male reproductive health. It is the changing pattern of several diseases or conditions that provides clues to their origins and the most convincing evidence of the importance of the fetal environment. Along with the increases in testicular cancer, many studies suggest that male fertility and sperm counts are declining in some parts of the world and the incidence of cryptorchidism (undescended testes) and hypospadias (an abnormality of the penis in which the opening is on the underside of the shaft rather than at the tip) is increasing.<sup>9</sup> <sup>10</sup>

## The Hormonal Environment

Considerable recent interest has focused on the role of hormonal factors in the development of testicular cancer. A large amount of research in laboratory animals and humans points to the importance of the period of fetal development in determining the subsequent risk of developing testicular cancer. This research can be summarized as follows:

Development of the male reproductive tract is under the control of hormones during fetal development. Of course, testosterone from the fetal testes plays an important role, but estrogen and pituitary hormones, among others, are also critical.<sup>12 13 14</sup>

Animal studies show that fetal exposure to estrogen or estrogenic chemicals can cause not only reduced sperm counts, cryptorchidism, and hypospadias, but also fundamental changes in the germ cells (immature sperm) that persist after birth and that may be precursors to cancerous changes in those cells.<sup>15 16 17</sup>

Animal studies also show that fetal exposure to anti-androgens, which block the action of testosterone or impair its synthesis, also cause similar abnormalities of male reproductive tract development. Anti-androgens for which this has been shown include the pesticides vinclozolin, procymidone, DDE, which is the metabolite of DDT, and some phthalates, which are plasticizers used in many different consumer products and which are almost universally present in the blood and urine of human populations.<sup>18</sup> <sup>19 20</sup>

Human studies also indicate that the risk of testicular cancer sharply increases with abnormalities of testis development, including non-descent into the scrotum and low sperm counts associated with infertility.<sup>21 22</sup> Numerous studies report an increased risk of testicular cancer in an undescended testis of 2-9 fold.<sup>23</sup> In a male with only one undescended testis, the excess cancer risk in the testis that has normally descended into the scrotum during development is not as large, but some studies find that the risk in that testis is also somewhat elevated.<sup>24</sup>

In humans, evidence that estrogenic exposures in the developing fetus play a role in increasing testicular cancer risk is inconclusive. Testicular cancer risks in male offspring are highest in first pregnancies, when estrogen levels are higher than in subsequent pregnancies.<sup>25 26</sup> Some evidence points to maternal estrogen exposure as increasing the risk of testicular cancer in their sons. In one study, the risk was increased 5 fold if a woman had used prescription hormones, prescription medications for conditions associated with threatened miscarriage, injections or pills to determine pregnancy, or oral contraceptives around the time of conception.<sup>27</sup> However, studies of sons born to mothers who took the synthetic estrogen, diethylstilbestrol (DES), during pregnancy show mixed results with some showing no significantly increased risk of testicular cancer.<sup>28</sup> The research on DES sons is complicated because testicular cancer remains relatively uncommon even though its incidence is increasing, and because gaps in record keeping often make it difficult to know with certainty whether or not a man with testicular cancer was actually exposed to DES during fetal development. To get around this latter limitation a 16-year prospective study followed over 3000 men whose prenatal DES exposure status was known.<sup>29</sup> The investigators reported that men who had been exposed to DES during fetal development had a 3 fold higher risk of developing testicular cancer, although even in this study, the number of participants and cases was small enough that the increased risk was not statistically significant. Nonetheless, the results support the hypothesis that fetal exposures to abnormal levels of estrogen increase the risk of subsequently developing testicular cancer. It is worth noting, however, that DES was not used in Denmark where testicular cancer risk is the highest in the world, so DES alone cannot explain the trends.

Other hormones, including testosterone and pituitary hormones also are likely to play a role, and environmental factors that alter their normal levels may also alter testicular cancer risk. Some investigators suggest that the marked difference in testicular cancer risk between blacks and whites can be explained by differences in hormone exposures during fetal development. In a study of 20 black women and 20 white women during their first pregnancies, testosterone levels in black women were 48% higher than those in white women in the early weeks of pregnancy.<sup>30</sup> Estrogen levels were only slightly higher in black women. It may be that the relative excess of testosterone exposure in black males during fetal development explains the lower testicular cancer risk in black men.

Pituitary hormones may also play a role. In boys with Down's syndrome, testicular cancer risk is elevated despite lower overall cancer risk when compared to the rest of the population.<sup>31</sup> In mothers who give birth to a boy with Down's syndrome, and in boys with Down's syndrome, pituitary hormones (follicle stimulating hormone and luteinizing hormone) are elevated.<sup>32 33</sup> Boys with Down's syndrome also have an increased risk of undescended testes.

Taken together these threads of evidence suggest that the fetal hormonal environment plays an important role in determining subsequent risk of developing testicular cancer. Elevated exposures to estrogen or estrogenic agents, decreased exposure to testosterone, and increased levels of pituitary hormones may all participate in increasing the risk. Maternal exposures to hormonally active agents such as birth control pills, some pesticides, phthalate plasticizers, and other industrial chemicals used in consumer products may alter the fetal hormonal environment and male reproductive tract development, including the testes. However, except for DES, there is no evidence in humans that abnormal male development has actually occurred as a result of

these exposures. Nevertheless, it is important to keep in mind that health effects that only become apparent decades after the exposure of concern make this an extremely difficult link to study and indirect evidence, along with a changing pattern of disease, may be the best evidence that will ever be available in human populations.

#### **Other Risk Factors**

In addition to evaluation of the fetal environment, a number of studies have tried to identify other testicular cancer risk factors. Contradictory or inconsistent findings for inguinal hernia, a history of mumps virus infection of the testis, and trauma as risk factors have been reported.<sup>34 35 36</sup> A large study in Great Britain found early onset of puberty and lack of exercise to be risk factors for testicular cancer.<sup>37</sup> Occupational exposures have also been investigated as possible causes of testicular cancer. In some studies, men who served in the military are at increased risk of testicular cancer.<sup>38 39</sup> Viet Nam veterans and military dogs used in Viet Nam were reported at an increased risk of testicular cancer.<sup>40 41</sup> Small increased risks for testicular cancer have also been reported in some studies of farmers, but not in others, and a 2.5 fold increased risk was reported in a study of licensed pesticide applicators.<sup>42 43</sup> In one study, occupational exposure to magnetic fields was also reported to increase the risk of testicular cancer up to four fold.<sup>44</sup>

#### Summary

The incidence of testicular cancer has sharply and steadily increased in many countries, including the United States, over the past 50 years. Genetic inheritance probably explains about 25% of cases and the rest are largely influenced by environmental factors not well understood. However, most investigators conclude that hormonal factors appear to play a role during fetal development in shaping subsequent testicular cancer risk. Estrogen, testosterone, pituitary hormones, and others play important roles in development of the male reproductive tract. Alterations in these hormone levels or exposure to exogenous agents with hormonal activity (endocrine disruptors) are likely to alter testicular development and testicular cancer risk. Evidence from animal and human studies implicate increased exposure to estrogen, estrogenic agents, or anti-androgens during fetal development. After birth, inconclusive evidence suggests that some pesticides and strong electromagnetic fields also increase testicular cancer risks.

<sup>&</sup>lt;sup>1</sup> Bosland M. Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. Prog Clin Biol Res 394:309-352, 1996.

<sup>&</sup>lt;sup>2</sup> SEER Cancer statistics review, 1973-1996 (NCI 1999) and Cancer rates and risks, 4<sup>th</sup> edition (NCI 1996).

<sup>&</sup>lt;sup>3</sup> Rajpert-De Meyts E, Skakkeboek N. The possible role of sex hormones in the development of testicular cancer. Eur Urol 23:54-61, 1993.

<sup>&</sup>lt;sup>4</sup> Kolonel L, Ross R, Thomas D, Thompson D. Epidemiology of testicular cancer in the Pacific Basin. Natl Cancer Inst Monogr 62:157-160, 1982.

<sup>&</sup>lt;sup>5</sup> Rapley E, Crockford G, Teare D, et al. Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet 24(2):197-200, 2000.

<sup>&</sup>lt;sup>6</sup> Nicholson P, Harland S. Inheritance and testicular cancer. Br J Cancer 71(2):421-426, 1995.

<sup>&</sup>lt;sup>7</sup> Czene K, Lichtenstein P, Hemminki K. Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish family-cancer database. Int J Cancer 99:26-266, 2002.

<sup>8</sup> Czene K, Lichtenstein P, Hemminki K. Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish family-cancer database. Int J Cancer 99:26-266, 2002.

<sup>9</sup> Sharpe R. Hormones and testis development and the possible adverse effects of environmental chemicals. Toxicol Lett 120:221-232, 2001.

<sup>10</sup> Toppari J, Larsen J, Christiansen P, et al. Male reproductive health and environmental xenoestrogens. Environ Health Perspect 104(suppl 4):741-803, 1996.

<sup>11</sup> See also CHE papers on prostate cancer and infertility for additional discussion of this topic

<sup>12</sup> Sharpe R. Do males rely on female hormones? Nature 390:447-448, 1997

<sup>13</sup> Hess R, Bunick D, Lee, K. A role for oestrogens in the male reproductive system. Nature 390:509-512, 1997.

<sup>14</sup> Sharpe R. Hormones and testis development and the possible adverse effects of environmental chemicals. Toxicol Lett 120:221-232, 2001.

<sup>15</sup> Khan S, Ball R, Hendry W. Effects of neonatal administration of diethylstilbestrol in male hamsters: disruption of reproductive function in adults after apparently normal pubertal development. Biol Reprod 58:137-142, 1998.
<sup>16</sup> Yasuda Y, Kihara T, Tanimura T. Effect of ethinyl estradiol on the differentiation of mouse fetal testis. Teratol

32:113-118, 1985.

<sup>17</sup> Toppari J, Larsen J, Christiansen P, et al. Male reproductive health and environmental xenoestrogens. Environ Health Perspect 104(suppl 4):741-803, 1996.

<sup>18</sup> Gray LE. Ostby J, Monosson E, et al. Environmental anti-androgens: low doses of the fungicide vinclozolin alter sexual differentiation of the male rat. Toxicol Indust Health 15:48-64, 1999.
<sup>19</sup> Gray L, Wolf C, Lambright C, et al. Adminstration of potentially antiandrogenic pesicides (procymidone, linuron,

<sup>19</sup> Gray L, Wolf C, Lambright C, et al. Administration of potentially antiandrogenic pesicides (procymidone, linuron, iprodione, chlozlinate, p,p'-DDE, and ketoconazole) and toxic substances (dibutyl- and diethylhexylphthalate, PCB 169, and ethane dimethan sulphonate) during sexual differentiation produces diverse profiles of reproductive malformations in the male rat. Toxicol Indust Health 15: 94-118, 1999.

<sup>20</sup> Blount B, Silva M, Caudill S, et al. Levels of seven urinary phthalate metabolites in a human reference population. Environ Health Perspect 108:972-982, 2000.

<sup>21</sup> Rajpert-DeMeyts E, Jorgensen N, Brondum-Nielsen K, et al. Developmental arrest of germ cells in the pathogenesis of germ cell neoplasia. APMIS 106:198-206, 1998.

<sup>22</sup> Moller H, Skakkebaek N. Risk of testicular cancer in subfertile men: case-control study. Brit Med J 318:559-562, 1999.

<sup>23</sup>Reviewed in: Bosland, 1996.

<sup>24</sup>Horwich A. Testicular germ cell tumors: an introductory overview. In: Testicular cancer—investigation and management. 2<sup>nd</sup> ed. Ed: Horwich A. London; Chapman and Hale Medical, 1996.

<sup>25</sup> Prener A, Hsieh C, Engholm G, et al. Birth order and risk of testicular cancer. Cancer Causes Control 3:265-272, 1992.

<sup>26</sup> Depue R, Pike M, Henderson B. Estrogen exposure during gestation and risk of testicular cancer. J Natl Cancer Inst 71:1151-1155, 1983.

<sup>27</sup> Weir H, Marrett L, Kreiger N, et al. Pre-natal and peri-natal exposures and risk of testicular germ-cell cancer. In J Cancer 87:438-443, 2000.

<sup>28</sup> Rajpert-De Meyts E, Skakkeboek N. The possible role of sex hormones in the development of testicular cancer. Eur Urol 23:54-61, 1993.

<sup>29</sup> Strohsnitter W, Noller K, Hoover R, et al. Cancer risk in men exposed in utero to diethylstilbestrol. J Natl Cancer Inst 93(7):545-551, 2001.

<sup>30</sup> Henderson B, Bernstein L, Ross R, et al. The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br J Cancer 57:216-218, 1988.

<sup>31</sup> Satge D, Sasco A, Cure H, et al. An excess of testicular germ cell tumors in Down's syndrome: three cases and a review of the literature. Cancer 80(5):929-935, 1997.

<sup>32</sup> United Kingdom Testicular Cancer Study Group. Actiology of testicular cancer: association with congenital abnormalities, age at puberty, infertility, and exercise. Brit Med J 308:1393-1399, 1994.

<sup>33</sup> Van Montfrans J, van Hooff M, Martens F, Lambalk C. Basal FSH, estradiol, and inhibin B concentrations in women with a previous Down's syndrome affected pregnancy. Hum Reprod 17(1):44-47, 2002.

<sup>34</sup> Gershman S, Stolley P. A case-control study of testicular cancer using Connecticut tumour registry data. Int J Epidemiol 17:738-742, 1988.

<sup>35</sup> Henderson B, Benton B, Jing J, et al. Risk factors for cancer of the testis in young men. Int J Cancer 23:598-602, 1979.

<sup>36</sup> Morris Brown L, Pottern L, Hoover R. Prenatal and perinatal risk factors for testicular cancer. Cancer Res 46:4812-4816, 1986.

<sup>37</sup> United Kingdon Testicular Cancer Study Group. Actiology of testicular cancer: association with congenital abnormalities, age at puberty, infertility, and exercise. Brit Med J 308:1393-1399, 1994.

<sup>38</sup> Olson J, Jensen O. Occupation and risk of cancer in Denmark. Scand J Work Environ Health 13:1-91, 1987.

<sup>39</sup> Dubrow R, Wegman D. Setting priorities for occupational cancer research and control: synthesis of the results of occupational disease surveillance studies. J Natl Cancer Inst 71:1123-1142, 1983.

<sup>40</sup> Tarone R, Hayes H, Hoover R, Rosenthal J, et al. Service in Viet Nam and risk of testicular cancer. J Natl Cancer Inst 83:1497-1499, 1991.

<sup>41</sup> Hayes H, Tarone R, Casey W, Huxsoll D. Excess of seminomas observed in Vietnam services US military working dogs. J Natl Cancer Inst 82:1042-1046, 1990. <sup>42</sup> Reviewed in: Bosland, 1996.

<sup>43</sup> Fleming L, Bean J, Rudolph M, Hamilton K. Cancer incidence in a cohort of licensed pesticide applicators in Florida. J Occup Environ Med 41(4):279-288, 1999.

<sup>44</sup> Floderus B, Stenlund C, Persson T. Occupational magnetic field exposure and site-specific cancer incidence: a Swedish cohort study. Cancer Causes Control 10(5):323-332, 1999.